ライフサイエンスコーパス: bowel disease

1 astrointestinal symptoms (e.g., inflammatory bowel disease).

2 s, such as allergy, asthma, and inflammatory bowel disease.

3 tive colitis, one form of human inflammatory bowel disease.

4 isease-modifying therapeutic of inflammatory bowel disease.

5 th vedolizumab in patients with inflammatory bowel disease.

6 IL10R) develop very early onset inflammatory bowel disease.

7 ntribute to the pathogenesis of inflammatory bowel disease.

8 d affect the natural history of inflammatory bowel disease.

9 T cell therapy in patients with inflammatory bowel disease.

10 suggested as a risk factor for inflammatory bowel disease.

11 mportant therapeutic targets in inflammatory bowel disease.

12 XP3(+) mice develop spontaneous inflammatory bowel disease.

13 more effective in patients with inflammatory bowel disease.

14 uality of life in patients with inflammatory bowel disease.

15 lay a pathogenic role including inflammatory bowel disease.

16 the evaluation of patients with inflammatory bowel disease.

17 s that has been associated with inflammatory bowel disease.

18 tive health outcomes, including inflammatory bowel disease.

19 highly effective treatment for inflammatory bowel disease.

20 encies and rare forms of severe inflammatory bowel disease.

21 tinal inflammatory responses in inflammatory bowel disease.

22 ciated with atherosclerosis and inflammatory bowel disease.

23 lastic changes in patients with inflammatory bowel disease.

24 ugs in paediatric patients with inflammatory bowel disease.

25 ment of mucosal inflammation or inflammatory bowel disease.

26 c inflammatory diseases such as inflammatory bowel disease.

27 rved in patients with ileus and inflammatory bowel disease.

28 the evaluation of patients with inflammatory bowel disease.

29 uch as rheumatoid arthritis and inflammatory bowel disease.

30 new option in the treatment of inflammatory bowel disease.

31 sociated with increased risk of inflammatory bowel disease.

32 d with susceptibility genes for inflammatory bowel disease.

33 d with rheumatoid arthritis and inflammatory bowel disease.

34 such as multiple sclerosis and inflammatory bowel disease.

35 approach to treat patients with inflammatory bowel disease.

36 roducing Th17 cells, leading to inflammatory bowel disease.

37 individuals with gastrointestinal/irritable bowel disease.

38 ocalin-2 (Lcn2) are observed in inflammatory bowel disease.

39 t a novel therapeutic target in inflammatory bowel disease.

40 eostasis and mucosal healing in inflammatory bowel disease.

41 ancers is present in those with inflammatory bowel disease.

42 odium sulfate mediated model of inflammatory bowel disease.

43 on are the principal factors in inflammatory bowel disease.

44 se with rheumatoid arthritis or inflammatory bowel disease.

45 resents a therapeutic target in inflammatory bowel disease.

46 ry diseases, such as asthma and inflammatory bowel disease.

47 such as cholestasis, NASH, and inflammatory bowel disease.

48 onic heart failure, cancer, and inflammatory bowel disease.

49 re used only to confirm the absence of small-bowel disease.

50 uality of life in patients with inflammatory bowel disease.

51 r a therapeutic avenue in treating irritable bowel disease.

52 previously reported cases with inflammatory bowel disease.

53 ase pathway in the pathogenesis of irritable bowel disease.

54 on and treatment strategies for inflammatory bowel disease.

55 ole of TDM in the management of inflammatory bowel disease.

56 hemoprevention in patients with inflammatory bowel disease.

57 contributes to pathogenesis of inflammatory bowel diseases.

58 tinal fibrosis in patients with inflammatory bowel diseases.

59 patterns associated with human inflammatory bowel diseases.

60 inflammatory diseases including inflammatory bowel diseases.

61 er, and promotes development of inflammatory bowel diseases.

62 contributes to pathogenesis of inflammatory bowel diseases.

63 as treatments for patients with inflammatory bowel diseases.

64 to resolve gut inflammation in inflammatory bowel diseases.

65 is, cardiovascular disease, and inflammatory bowel diseases.

66 ical feature of colitis and the inflammatory bowel diseases.

67 ay offer therapeutic options in inflammatory bowel diseases.

68 receiving treatment for chronic inflammatory bowel disease, 12.1% of the participants were recruited

69 29Q) knock-in mice developed an inflammatory bowel disease affecting both the small bowel and colon.

70 (RCTs) recruiting patients with inflammatory bowel disease aged at least 16 years that compared psych

71 presence and risk of new-onset inflammatory bowel disease, although the prevalence remained low.

72 ation in experimental models of inflammatory bowel disease and acute graft-versus-host disease (GVHD)

73 er models, including autoimmune inflammatory bowel disease and allogeneic graft-versus-host disease.

74 se models, including a model of inflammatory bowel disease and an inflammatory arthritis model.

75 een associated with early-onset inflammatory bowel disease and colon cancer.

76 agilis (ETBF) is linked to both inflammatory bowel disease and colorectal cancer and, in our murine m

77 s (ETBF) has been implicated in inflammatory bowel disease and colorectal cancer; however, colonizati

78 nvolves assessment for comorbid inflammatory bowel disease and exclusion of other associated cholangi

79 ow to best manage patients with inflammatory bowel disease and flat low-grade dysplasia (fLGD) in the

80 -/-) T cells caused more severe inflammatory bowel disease and graft-versus-host disease and produced

81 for research into prevention of inflammatory bowel disease and innovations in health-care systems to

82 Disorders, such as inflammatory bowel disease and irritable bowel syndrome, are associat

83 osus (SLE), Sjogren's syndrome, inflammatory bowel disease and multiple sclerosis.

84 inflammatory disorders such as inflammatory bowel disease and rheumatoid arthritis.

85 seases such as atherosclerosis, inflammatory bowel disease and systemic lupus erythematosus.

86 hronic inflammation of the gut (inflammatory bowel disease) and lung (chronic obstructive pulmonary d

87 lthy controls, 40 controls with inflammatory bowel disease, and 327 consecutive patients with cirrhos

88 ted respiratory disease (AERD), inflammatory bowel disease, and acute respiratory distress syndrome.

89 ory diseases, including asthma, inflammatory bowel disease, and arthritis.

90 stridium difficile infection or inflammatory bowel disease, and most (87%) were non-randomized contro

91 idity burden, previous surgery, inflammatory bowel disease, and procedure type.

92 autoimmune disorders, including inflammatory bowel disease, and thus are widely considered to be path

93 , diabetes, obesity, arthritis, inflammatory bowel diseases, and even neuropsychiatric disorders.

94 ative colitis are heterogeneous inflammatory bowel diseases, and therapeutic requirements vary among

95 reatment effects in early-onset inflammatory bowel disease are less certain.

96 Inflammatory bowel diseases are chronic gastrointestinal inflammatory

97 Strategies for management of inflammatory bowel diseases are shifting from simple control of sympt

98 Pathologic states, such as inflammatory bowel disease, are associated with a leaky epithelial ba

99 ing incidence and prevalence of inflammatory bowel disease around the world.

100 of this serious complication of inflammatory bowel diseases, as well as factors that predict its prog

101 mportant therapeutic target for inflammatory bowel disease-associated diarrhea.

102 ion studies have identified 200 inflammatory bowel disease-associated loci, but few have been conclus

103 l adenocarcinoma, as well as in inflammatory bowel disease-associated SBAs.

104 Inflammatory bowel diseases-associated fibrosis was seen as an irreve

105 study of 80 pregnant women with inflammatory bowel diseases at tertiary hospitals in Denmark, Austral

106 elvic inflammatory disease, and inflammatory bowel diseases-at a concentration range of 1-100ng/mL in

107 betes mellitus, celiac disease, inflammatory bowel disease, autoimmune thyroid disease, and juvenile

108 (GCs) are widely used to treat inflammatory bowel disease but their effect on intestinal leukocyte h

109 nal epithelium of patients with inflammatory bowel disease, but its role in pathogenesis is uncertain

110 nt roles in human metabolic and inflammatory bowel diseases, but a role in host response to microbes

111 d antibiotics for patients with inflammatory bowel diseases, but are these immunotherapies ready for

112 Inflammatory bowel disease causes chronic, relapsing intestinal infla

113 om women without a diagnosis of inflammatory bowel disease, celiac disease, or liver disease, endosco

114 DC-LMP1/CD40 chimeras developed inflammatory bowel disease characterized by massive transmural influx

115 tic association in the Manitoba Inflammatory Bowel Disease Cohort Study was conducted through the gen

116 educe many clinical features of inflammatory bowel disease, complete mucosal healing occurs in fewer

117 No inflammatory bowel disease control had S-ANT <15.

118 e and other diseases, including inflammatory bowel disease, Crohn's disease and rheumatoid arthritis.

119 atory disease) and 30ng/mL (for inflammatory bowel diseases) CRP in 1000-fold diluted blood respectiv

120 logic conditions, malignancies, inflammatory bowel disease, dermatologic conditions, or solid-organ o

121 prevalence of paediatric-onset inflammatory bowel disease (diagnosis at age <16 years) were excluded

122 The prevalence of inflammatory bowel disease exceeded 0.3% in North America, Oceania, a

123 s conferring protection against inflammatory bowel disease exploiting knowledge of common variants as

124 terographic images for the presence of small-bowel diseases, for differentiating between inflammatory

125 ng surveillance colonoscopy for inflammatory bowel disease from 1990 to 2015 at the University of Cal

126 International Inflammatory Bowel Disease Genetics Consortium members funding source

127 nority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5% [n = 2/19]

128 t the turn of the 21st century, inflammatory bowel disease has become a global disease with accelerat

129 In small studies, inflammatory bowel disease has been associated with the increased pre

130 ia management for patients with inflammatory bowel disease has changed since this first case report,

131 volving genetic architecture of inflammatory bowel disease has deepened our understanding of its path

132 of the genetic underpinnings of inflammatory bowel disease has made great progress since the identifi

133 AIMS: Diarrhea associated with inflammatory bowel diseases has been associated with increased levels

134 estinal mucosa of patients with inflammatory bowel diseases has reduced expression of solute carrier

135 -occurrence in individuals with inflammatory bowel disease (IBD) and healthy (non-IBD control) indivi

136 ever, health conditions such as inflammatory bowel disease (IBD) are associated with a reduced mucus

137 Most children with Inflammatory Bowel Disease (IBD) are diagnosed between 11 and 16 year

138 Obesity and inflammatory bowel disease (IBD) are systemic inflammatory disorders

139 plex genetic basis of polygenic inflammatory bowel disease (IBD) as well as Mendelian disease-associa

140 presumably plays a key role in inflammatory bowel disease (IBD) development.

141 ing of genetic underpinnings of inflammatory bowel disease (IBD) has undergone a revolution, based in

142 s (CDIs) among individuals with inflammatory bowel disease (IBD) have used data from single centers o

143 : Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to

144 ed in the diagnostic workup for inflammatory bowel disease (IBD) in pediatric patients.

145 Inflammatory bowel disease (IBD) involves interaction between host ge

146 Inflammatory bowel disease (IBD) is a chronic inflammatory disease of

147 Inflammatory bowel disease (IBD) is a chronic inflammatory disorder a

148 Inflammatory bowel disease (IBD) is an autoimmune condition that is d

149 Inflammatory bowel disease (IBD) is associated with altered microbiot

150 Inflammatory bowel disease (IBD) is associated with increased intesti

151 Inflammatory bowel disease (IBD) is associated with risk variants in

152 Inflammatory bowel disease (IBD) is characterized by dysregulation in

153 Inflammatory bowel disease (IBD) is characterized by flares of inflam

154 Inflammatory bowel disease (IBD) is difficult to diagnose due to nons

155 intestinal inflammation during inflammatory bowel disease (IBD) is poorly defined.

156 A major challenge in inflammatory bowel disease (IBD) is the integration of diverse IBD da

157 obacco smoke in the etiology of inflammatory bowel disease (IBD) is unclear.

158 question asked by patients with inflammatory bowel disease (IBD) is, "Doctor, what should I eat?" Fin

159 ion studies have identified 200 inflammatory bowel disease (IBD) loci, but the genetic architecture o

160 regulated by variants linked to inflammatory bowel disease (IBD) not only outperform genetic risk sco

161 Real-life data on inflammatory bowel disease (IBD) prevalence and costs are scarce.

162 blood samples of patients with inflammatory bowel disease (IBD) receiving anti-TNF therapy.

163 available medical therapies of inflammatory bowel disease (IBD) remains controversial.

164 Children and adolescents with inflammatory bowel disease (IBD) report impairments in daily activiti

165 Conversely, patients with inflammatory bowel disease (IBD) that carried an autoimmunity-associa

166 Severe forms of inflammatory bowel disease (IBD) that develop in very young children

167 RD9), a susceptibility gene for inflammatory bowel disease (IBD) that functions in the immune respons

168 he increased risks conferred by inflammatory bowel disease (IBD) to the development of colorectal can

169 ecision making in patients with inflammatory bowel disease (IBD) who lose response to anti-TNF therap

170 hronic inflammatory conditions (inflammatory bowel disease (IBD)) can be identified.

171 ciated with Crohn's disease, an inflammatory bowel disease (IBD), and poor survival in allogeneic hem

172 )-associated colitis or without inflammatory bowel disease (IBD), and whether expression levels are a

173 TNF plays an integral role in inflammatory bowel disease (IBD), as evidenced by the dramatic therap

174 sociated with disorders such as inflammatory bowel disease (IBD), but the mechanisms of this process

175 In inflammatory bowel disease (IBD), compromised restitution of the epit

176 on the prevalence of paediatric inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative

177 Inflammatory bowel disease (IBD), including Crohn disease and ulcerat

178 thologies of the two main forms of irritable bowel disease (IBD), ulcerative colitis (UC), and Crohn'

179 y is essential for the onset of inflammatory bowel disease (IBD), yet the specific mechanism by which

180 g its efficacy in patients with inflammatory bowel disease (IBD).

181 y 75% of patients have comorbid inflammatory bowel disease (IBD).

182 macrophages in a mouse model of inflammatory bowel disease (IBD).

183 een associated with the risk of inflammatory bowel disease (IBD).

184 s that are linked to asthma and inflammatory bowel disease (IBD).

185 ncluding obesity, diabetes, and inflammatory bowel disease (IBD).

186 iliary disorder associated with inflammatory bowel disease (IBD).

187 ve colitis, a major category of inflammatory bowel disease (IBD).

188 ients receiving thiopurines for inflammatory bowel disease (IBD).

189 deficiency is a risk factor for inflammatory bowel disease (IBD).

190 e initiation and progression of inflammatory bowel disease (IBD).

191 t LANCL2-based therapeutics for inflammatory bowel disease (IBD).

192 f rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).

193 le in the pathogenesis of human inflammatory bowel disease (IBD).

194 icious cycle leading to chronic inflammatory bowel disease (IBD).

195 used for treating patients with inflammatory bowel disease (IBD).

196 adenomatosis polyposis (FAP) or inflammatory bowel disease (IBD).

197 e incidence and pathogenesis of inflammatory bowel disease (IBD).

198 key role in the pathogenesis of inflammatory bowel disease (IBD).

199 megalovirus (CMV) infection and inflammatory bowel disease (IBD).

200 set and enhance the severity of inflammatory bowel disease (IBD).

201 e been associated with risk for inflammatory bowel disease (IBD).

202 ased risk of or protection from inflammatory bowel disease (IBD).

203 -PMPA) as a novel treatment for inflammatory bowel disease (IBD).

204 ically developing children with inflammatory bowel disease (IBD; i.e. Crohn's disease or ulcerative c

205 Inflammatory bowel diseases (IBD) affect over 5 million individuals i

206 its effects in mouse models of inflammatory bowel diseases (IBD) and intestinal mucosal healing.

207 Inflammatory bowel diseases (IBD) are likely driven by aberrant immun

208 OUND & AIMS: Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diar

209 r immune responses that mediate inflammatory bowel diseases (IBD) in humans and enterocolitis in mice

210 BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) increase risk for colorectal cancer

211 BACKGROUND & AIMS: Diagnosis of inflammatory bowel diseases (IBD) is increasing among elderly persons

212 f children newly diagnosed with inflammatory bowel diseases (IBD) to learn more about pathogenesis.

213 BACKGROUND & AIMS: The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's

214 for therapeutic application in inflammatory bowel diseases (IBD) yet understanding of the underlying

215 ts metabolites in patients with inflammatory bowel diseases (IBD), and study their association with c

216 Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and

217 Inflammatory bowel diseases (IBD), such as Crohn disease and ulcerati

218 plicated in the pathogenesis of inflammatory bowel diseases (IBD).

219 Cs systemically administered in inflammatory bowel diseases (IBD).

220 Inflammatory bowel diseases (IBDs) are a set of complex and debilitat

221 Inflammatory bowel diseases (IBDs) are chronic and impose significant

222 Inflammatory bowel diseases (IBDs) are defined as chronic relapsing i

223 sights into the pathogenesis of inflammatory bowel diseases (IBDs) have provided important informatio

224 BACKGROUND & AIMS: Inflammatory bowel diseases (IBDs) increase the risk of colorectal ca

225 robiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation.

226 lammatory conditions, including inflammatory bowel diseases (IBDs), herein we investigate expression

227 hogenic factor in patients with inflammatory bowel diseases (IBDs), the molecular pathways driving di

228 e altered during development of inflammatory bowel diseases (IBDs).

229 or nonallopathic therapies, for inflammatory bowel diseases (IBDs).

230 general population, the risk of inflammatory bowel disease in children was 80 times higher, and the r

231 able or decreasing incidence of inflammatory bowel disease in North America and Europe.

232 the data on the concurrence of inflammatory bowel disease in patients with HS are limited.

233 ated the prevalence and risk of inflammatory bowel disease in patients with HS compared with the gene

234 her diseases, including asthma, inflammatory bowel disease, infections, cerebral palsy, dilated cardi

235 Inflammatory bowel diseases involve the dynamic interaction of host g

236 Infantile-onset inflammatory bowel disease (IO IBD) is an invalidating illness with a

237 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic

238 Inflammatory bowel disease is a global disease in the 21st century.

239 Inflammatory bowel disease is associated with psychological comorbidi

240 nt of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misi

241 Heritability of early-onset inflammatory bowel disease is hypothesised to be between that of infa

242 dence of early-onset paediatric inflammatory bowel disease is increasing worldwide.

243 Inflammatory bowel disease is thought to arise from inappropriate inf

244 However, the effect of AS II on inflammatory bowel disease is unknown.

245 The pathology of inflammatory bowel diseases is driven by the inflammatory signaling p

246 function in the pathogenesis of inflammatory bowel disease, ischemia-reperfusion injury, enteroinvasi

247 re we report fine-mapping of 94 inflammatory bowel disease loci using high-density genotyping in 67,8

248 ssociated with subphenotypes of inflammatory bowel disease, mainly disease location (essentially fixe

249 n established between IL-33 and inflammatory bowel disease, mechanistic studies to date, primarily us

250 benefits of using each class of inflammatory bowel disease medication.

251 es), and disease features (with inflammatory bowel disease, mesenteric vascular diseases, or other co

252 eases (rheumatoid arthritis and inflammatory bowel disease), metabolic diseases (atherosclerosis, dia

253 In patients with inflammatory bowel diseases, microbiota-reactive CD4(+) T cells were

254 tivity of TR1 cells in a murine inflammatory bowel disease model, a model that resembles the trials p

255 ied 163 susceptibility loci for inflammatory bowel disease, mostly shared between Crohn's disease and

256 an CT enterography in the detection of small-bowel diseases; MR enterography was more accurate in det

257 a continuum of disorders within inflammatory bowel disease, much better explained by three groups (il

258 s, n = 13-30) and patients with inflammatory bowel diseases (n = 119; 59 with ulcerative colitis and

259 = 74) or from patients without inflammatory bowel diseases (n = 22), to measure levels of GATA3.

260 e of the heavy burden of severe inflammatory bowel disease on patients' health and quality of life, a

261 years), who were suspected of having a small-bowel disease on the basis of clinical findings and whos

262 scopy was performed to rule out inflammatory bowel disease or gastrointestinal neoplasm as a cause of

263 nvestigated in individuals with inflammatory bowel diseases or solid-organ transplants, virome dynami

264 aphy for the detection of both overall small-bowel diseases (P = .0159) and neoplastic diseases (P =

265 in a mouse model of colitis and inflammatory bowel disease patients, and this results in dysregulated

266 standing of heterogeneity among inflammatory bowel disease patients.

267 ed with the histology scores of inflammatory bowel disease patients.

268 lated in inflamed biopsies from inflammatory bowel disease patients.

269 Pediatric inflammatory bowel disease (pIBD) is a chronic heterogeneous disorder

270 Paediatric inflammatory bowel disease (PIBD), comprising Crohn's disease (CD), u

271 iorate rheumatoid arthritis and inflammatory bowel disease provide a path for using electrons as a th

272 come was quality of life on the Inflammatory Bowel Disease Questionnaire (IBDQ) at 12 months.

273 bowel component of the modified Inflammatory Bowel Disease Questionnaire (IBDQ) score and the IBDQ re

274 sease Activity Index (CDAI) and Inflammatory Bowel Disease Questionnaire (IBDQ) scores to evaluate di

275 een groups in the change in the Inflammatory Bowel Disease Questionnaire-Bowel Subset (IBDQ-B) score

276 is of many disorders, including inflammatory bowel disease, sepsis, and inflammatory arthritis.

277 ting all known risk alleles for inflammatory bowel disease showed strong association with disease sub

278 sia detection and management in inflammatory bowel disease since 1925, the year the first case report

279 Increasing incidence of inflammatory bowel diseases, such as Crohn's disease, in developed na

280 In patients with active inflammatory bowel disease the mucosal frequencies of CD8alphabeta(+)

281 atment can alter progression of inflammatory bowel diseases, the importance of examining objective si

282 gy that can be used to optimize inflammatory bowel disease therapeutics.

283 r function in disorders such as inflammatory bowel disease, there has been long-standing interest in

284 ve identified 215 risk loci for inflammatory bowel disease, thereby uncovering fundamental aspects of

285 ve TDM (in patients with active inflammatory bowel disease) to guide treatment changes compared with

286 ive effect in the management of inflammatory bowel disease, treatment effects in early-onset inflamma

287 the genetic architecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, w

288 D), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU) is a complex and multi

289 disease, ulcerative colitis, or inflammatory bowel disease unclassified before the age of 10 years, t

290 6 with CD, 583 with UC, and 116 inflammatory bowel disease unclassified) and 5002 individuals without

291 2 (XLP-2) and very-early-onset inflammatory bowel disease (VEO-IBD).

292 inal tissues from patients with inflammatory bowel diseases vs controls, we found that reactivity to

293 ic risk (e.g., genetic risk for inflammatory bowel disease was negatively correlated with plasma cyst

294 otective role in infectious and inflammatory bowel diseases, whereas both beneficial and detrimental

295 ere suppressed in patients with inflammatory bowel disease who were on ARB therapy compared to patien

296 total of 27 pouch patients with inflammatory bowel diseases, who underwent pelvic MRI-DIXON and CT sc

297 ve risk of relapse of quiescent inflammatory bowel disease with psychological therapy versus control

298 nical management strategies for inflammatory bowel disease with the use of EGCG treatment.

299 Isolated inflammatory bowel disease without primary sclerosing cholangitis was

300 mmatory properties in models of inflammatory bowel disease, yet the underlying molecular mechanism is